1. Federal Court Infringement Analysis and Claim Construction
A plaintiff filing a lawsuit in federal district court must plead specific facts showing how an accused product meets the claim limitations. Federal Rule of Civil Procedure 8 requires the patent owner to identify the exact biological sequences at issue. Courts dismiss complaints relying on generic allegations without detailing the underlying molecular structures.
Discovery and Expert Testimony Phase
Litigants conduct discovery to uncover specific evidence supporting their technical arguments:
- Laboratory notebooks and clinical trial data.
- Internal emails regarding product development.
- Expert depositions evaluating biological functions.
Federal judges frequently rely on these technical records and expert reports to determine the scope of technical terms during summary judgment proceedings.
Intrinsic Evidence in Complex Biologics
Federal judges determine the legal boundaries of patent claims during Markman hearings before a jury trial begins. The court interprets disputed technical terms by examining the intrinsic evidence, including the patent specification and prosecution history. For gene-editing technologies, minor differences in defining an RNA sequence frequently dictate the outcome of the infringement action.
2. Administrative Patent Challenges and Regulatory Timelines
Accused infringers typically file petitions for inter partes review at the Patent Trial and Appeal Board to cancel patent claims based on prior art. The petitioner must establish a reasonable likelihood of prevailing on at least one challenged claim to institute the administrative trial. Administrative patent judges evaluate obviousness arguments using a preponderance of the evidence standard.
Coordination with District Court Litigation
Defendants file motions to stay the parallel district court litigation while the administrative board reviews the validity. District court judges grant these stays when the administrative proceeding has a high probability of simplifying the core issues for trial. Litigants coordinate their arguments across both forums to avoid inconsistent statements regarding the claim scope.
Standard of Review for Obviousness
The administrative board evaluates prior art references to determine whether a person of ordinary skill in the field would have combined them. Patent owners submit expert declarations demonstrating that the invention produced unexpected results compared to the prior art. The board issues a final written decision within one year of instituting the formal review process.
3. Subject Matter Eligibility and Generic Drug Equivalents
The Hatch-Waxman Act establishes a framework for generic drug manufacturers to challenge patents covering small molecule pharmaceuticals. A generic applicant files an Abbreviated New Drug Application containing a Paragraph IV certification stating the listed patents are invalid or not infringed. The patent owner has 45 days to file a lawsuit to trigger a 30-month stay.
The 30-Month Stay Provision
The 30-month stay prevents the FDA from approving the generic drug while the federal court resolves the underlying patent dispute. If the court finds the patent invalid or not infringed before the 30 months expire, the FDA approves the application immediately. Litigants frequently request expedited case schedules to reach a final judgment within this statutory window.
Diagnostic Method Patents Eligibility
Federal courts routinely invalidate patent claims attempting to monopolize natural phenomena under 35 U.S.C. Section 101. The Supreme Court requires claims directed to laws of nature to include an inventive concept transforming the discovery into a patent-eligible application. Attorneys analyze Federal Circuit decisions to determine which physical transformations satisfy this strict legal requirement.
4. Patent Term Extensions and Fda Approval Coordination
The United States Patent and Trademark Office grants a term extension to compensate for time lost during the mandatory FDA regulatory review process. Under 35 U.S.C. Section 156, a patent owner must file a formal application for extension within 60 days of receiving FDA approval. Failure to submit the application before this strict deadline results in forfeiture of the extension rights.
Calculation of the Extension Period
The agency calculates the extension using a specific statutory formula:
- Adding one-half of the clinical testing time to the entire time spent in the final FDA approval phase.
- Capping the total potential extension at a maximum of five years.
- Limiting the remaining patent term from the FDA approval date to 14 years.
Attorneys review the administrative record to confirm the agency applied the correct mathematical formula to the testing phases.
Eligibility Requirements for Active Ingredients
The statutory extension applies only to the first permitted commercial marketing of the specific active ingredient. Patent owners cannot obtain multiple extensions for the same patent based on different FDA approvals for new indications. The patent must claim the approved product, a method of using it, or a method of manufacturing it to qualify.
5. Biosimilar Litigation and Statutory Disclosure Procedures
The Biologics Price Competition and Innovation Act creates a distinct statutory pathway to resolve patent disputes before a competing biological product enters the market. The statute requires the biosimilar applicant to provide its abbreviated biologic license application and manufacturing information to the reference product sponsor within 20 days.
Identifying Asserted Patents for Trial
The reference product sponsor evaluates the manufacturing data to identify which patents the biosimilar likely infringes. The parties negotiate a final list of patents to litigate in the first phase of the federal lawsuit. Failing to include a relevant patent on the initial list bars the sponsor from asserting that patent later in the process.
Notice of Commercial Marketing
The biosimilar applicant must provide notice to the reference product sponsor at least 180 days before launching the product commercially. This notice period allows the sponsor to seek a preliminary injunction in federal court based on any patents not litigated in the first phase. Federal courts strictly enforce this timeline to provide sufficient time for equitable relief hearings.
6. Frequently Asked Questions
What triggers a 30-month stay in Hatch-Waxman litigation?
A generic drug maker filing an Abbreviated New Drug Application with a Paragraph IV certification triggers a 45-day window. If the patent owner files an infringement lawsuit within those 45 days, the statute imposes an automatic 30-month stay on FDA approval while the court resolves the dispute.
Can a patent owner extend a biotechnology patent term for multiple FDA approvals?
No. Under 35 U.S.C. Section 156, the federal statute limits the extension to the first permitted commercial marketing of the specific active ingredient. Patent owners cannot obtain multiple extensions for the same patent based on new dosages or indications.
What standard of proof applies to PTAB invalidity challenges?
Administrative patent judges at the PTAB evaluate obviousness arguments using a preponderance of the evidence standard. This requires less evidence than the clear and convincing standard applied by federal district courts during infringement trials.
13 Feb, 2026
